Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
9665390
Reference Type
Journal Article
Subtype
Review
Title
Approach to the patient with amiodarone-induced thyrotoxicosis
Author(s)
Bogazzi, F; Bartalena, L; Martino, E
Year
2010
Is Peer Reviewed?
Yes
Journal
Journal of Clinical Endocrinology and Metabolism
ISSN:
0021-972X
EISSN:
1945-7197
Volume
95
Issue
6
Page Numbers
2529-2535
Language
English
PMID
20525904
DOI
10.1210/jc.2010-0180
Web of Science Id
WOS:000278444000003
Abstract
Amiodarone, a benzofuranic iodine-rich antiarrhythmic drug, causes thyroid dysfunction in 15-20% of cases. Although amiodarone-induced hypothyroidism poses no particular problem, amiodarone-induced thyrotoxicosis (AIT) is a diagnostic and therapeutic challenge. There are two main forms of AIT: type 1, a form of iodine-induced hyperthyroidism, and type 2, a drug-induced destructive thyroiditis. However, mixed/indefinite forms exist that may be caused by both pathogenic mechanisms. Type 1 AIT usually occurs in abnormal thyroid glands, whereas type 2 AIT develops in apparently normal thyroid glands (or small goiters). Diagnosis of thyrotoxicosis is easy, based on the finding of increased free thyroid hormone concentrations and suppressed TSH levels. Thyroid radioactive iodine (RAI) uptake values are usually very low/suppressed in type 2 AIT, most commonly low or low-normal, but sometimes normal or increased in type 1 AIT despite the iodine load. Color flow Doppler sonography shows absent hypervascularity in type 2 and increased vascularity in type 1 AIT. Mixed/indefinite forms may have features of both AIT types. Thionamides represent the first-line treatment for type 1 AIT, but the iodine-replete gland is not very responsive; potassium perchlorate, by inhibiting thyroid iodine uptake, may increase the response to thionamides. Type 2 AIT is best treated by oral glucocorticoids. The response very much depends on the thyroid volume and the severity of thyrotoxicosis. Mixed/indefinite forms may require a combination of thionamides, potassium perchlorate, and steroids. RAI is usually not feasible in AIT due to low RAI uptake values. Thyroidectomy represents a valid option in cases resistant to medical therapy.
Keywords
Anti-Arrhythmia Agents; Biomarkers; Iodine Radioisotopes; Technetium Tc 99m Sestamibi; 971Z4W1S09; Amiodarone; N3RQ532IUT; Index Medicus; Thyroid Function Tests; Ultrasonography; Iodine Radioisotopes -- pharmacokinetics; Positron-Emission Tomography; Thyroid Gland -- diagnostic imaging; Thyrotoxicosis -- diagnostic imaging; Amiodarone -- adverse effects; Amiodarone -- therapeutic use; Thyrotoxicosis -- therapy; Thyrotoxicosis -- chemically induced; Anti-Arrhythmia Agents -- therapeutic use; Atrial Fibrillation -- drug therapy; Anti-Arrhythmia Agents -- adverse effects; Atrial Fibrillation -- complications
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity